Abeona Therapeutics Email Format

Biotechnology ResearchOhio, United States201-500 Employees

Abeona Therapeutics is a commercial-stage biotechnology company focused on cell and gene therapies for serious diseases. Its lead therapy, ZEVASKYN (prademagene zamikeracel), is an autologous, cell-based gene therapy designed to treat wounds in adults and children with recessive dystrophic epidermolysis bullosa. The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio that supports commercial production of ZEVASKYN. In addition to ZEVASKYN, Abeona is pursuing therapies for ophthalmic diseases and is exploring next-generation approaches to broaden tissue targeting.

ZEVASKYN is delivered to patients through a network of Qualified Treatment Centers, reflecting its status as a clinically available therapy. In 2026, Abeona expanded access by opening a new treatment center in New York, broadening geographic availability. The company is based in Cleveland and has a mid-sized workforce focused on advancing both the commercial and development programs.

Sign up for free to view info

Company overview Employee directory